SHANGHAI – In the almost two years since Chinese police said they were investigating Glaxosmithkline plc for corruption, the industry here has seen compliance go from a mid-level priority, second to meeting ambitious sales targets, to a board-level issue directly concerning senior management teams and those legally responsible for the business.